![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
This article presents a brief review of the physiologic abnormalities seen in fibromyalgia, current theories of widespread pain, and treatment options, including emerging therapeutics, with a focus on the use of duloxetine to manage fibromyalgia symptoms. Major clinical trials that examine the efficacy and effectiveness of duloxetine to date are reviewed, and safety issues are discussed.
Financial & competing interests disclosure
This work was supported by NIH grants NINR (NR0007061), NCCAM (AT002688), NINR (NR0007061) and 1R21AR056751-01. In addition to NIH grant support, Kim D Jones receives grant support from Merck, Jazz and Forest Pharmaceuticals, and is on the Speaker Bureau for Pfizer, Lilly, Jazz and Forest Pharmaceuticals. In addition to NIH grant support, Rebecca L Ross is on the Speaker Bureau for Lilly and Jazz Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.